By definition, the ACH2.0-based drugs are the agents that either deplete iAβ (and thus remove the trigger of conventional AD when applied preventively) and/or C99 (and thus abolish both the driver of the disease and the sustainer of its own AβPP-independent production) via their selective degradation or terminate the activity of the AβPP-independent C99 generation pathway in any other way. Here, APP is linked to Alzheimer disease.